P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE
Introduction and Objectives: The clinical alterations of Minimal Hepatic Encephalopathy (MHE) include subtle changes in cognitive processes detectable only with tests such as the Psychometric hepatic encephalopathy score (PHES) and critical blink rate (FCP) or P300 cognitive evoked potentials. After...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268123000595 |
| _version_ | 1797862193719410688 |
|---|---|
| author | José Luis Pérez-Hernández Christian Hinojosa-Segura Diana Montemira-Orozco Andrés Burak-Leipuner Juana Zavala-Ramírez Imram Cruz-Reyes María Escobedo-Silva Fátima Higuera-de la Tijera Daniel Santana-Vargas |
| author_facet | José Luis Pérez-Hernández Christian Hinojosa-Segura Diana Montemira-Orozco Andrés Burak-Leipuner Juana Zavala-Ramírez Imram Cruz-Reyes María Escobedo-Silva Fátima Higuera-de la Tijera Daniel Santana-Vargas |
| author_sort | José Luis Pérez-Hernández |
| collection | DOAJ |
| description | Introduction and Objectives: The clinical alterations of Minimal Hepatic Encephalopathy (MHE) include subtle changes in cognitive processes detectable only with tests such as the Psychometric hepatic encephalopathy score (PHES) and critical blink rate (FCP) or P300 cognitive evoked potentials. After treatment with L-Ornithine, L-Aspartate (LOLA) 18 grams/30 days, a decrease or normalization in the PHES score, an increase in FCP, and a reduction in the latency of the P300 potential have been observed. In the short term, it is unknown if there are changes in these three indicators of the cognitive status of patients with MHE. This study aimed to detect changes in the potential cognitive P300 of patients treated with LOLA 18g/3 days. Materials and Methods: Cirrhotic patients who attended the Liver Clinic of the Gastroenterology Service of the General Hospital of Mexico ''Eduardo Liceaga'' were included. The PHES test and FCP were applied, and the electroencephalogram (EEG) was recorded while visual stimuli were presented in a cognitive task to obtain the potential P300. The criteria for MHE were a PHES test score of less than -4 standard deviations (sd) and an FCP score of less than 39.0 Hz. EHM patients were given LOLA 6g/3 times a day for three days. Subsequently, the PHES, FCP, and P300 tests were repeated. Results: 89 patients with liver cirrhosis participated, 54 women (60.7%) with 53±7.9 years of age and 8.3±3.4 years of schooling. Fifty-seven patients (64.0%) were positive for PHES and 64 were positive for FCP (71.9%). EHM (positive for PHES and FCP) was detected in 53 patients (59.6%). Thirty-six patients (68%) accepted treatment with LOLA or completed the three tests, of which 16 repeated the three tests. The median PHES before treatment was -5.0 ds(-1,-6) and after treatment with LOLA -3.0 ds(-2,-4). The difference was significant in the Wilcoxon test for paired samples p<0.0001. The initial mean of the FCP was 37.03±1.8 Hz and the final was 39.8±2.1 Hz. The difference was significant for the student's t-test for related samples p<0.0001. The P300 potential had an initial amplitude of 2.42±2.79 and a final one of 2.21±2.19, not being significant, in contrast to the initial latency of 410.06±63 milliseconds (ms) and the final one of 404.88±63.6 ms, being significant after treatment. with LOLA p=0.015 Conclusions: Short-term (3 days) changes in MHE due to LOLA treatment were seen in PHES test scores, FCP test scores, and P300 evoked potentials. The P300 potentials reflect the state of the EEG when performing cognitive tasks of attention. The improvement in this indicator is already known at 30 days of treatment and with the present study, it was determined that immediately at the start of treatment with LOLA, there is an improvement in their cognitive status. |
| first_indexed | 2024-04-09T22:16:22Z |
| format | Article |
| id | doaj.art-9a8adb3678f44148b1e629c4bf6123ff |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-04-09T22:16:22Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-9a8adb3678f44148b1e629c4bf6123ff2023-03-23T04:34:08ZengElsevierAnnals of Hepatology1665-26812023-03-0128100955P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATEJosé Luis Pérez-Hernández0Christian Hinojosa-Segura1Diana Montemira-Orozco2Andrés Burak-Leipuner3Juana Zavala-Ramírez4Imram Cruz-Reyes5María Escobedo-Silva6Fátima Higuera-de la Tijera7Daniel Santana-Vargas8Department of Gastroenterology and Hepatology, General Hospital of México “Dr. Eduardo Liceaga,” Mexico City, MexicoDepartment of Gastroenterology and Hepatology, General Hospital of México “Dr. Eduardo Liceaga,” Mexico City, MexicoDepartment of Gastroenterology and Hepatology, General Hospital of México “Dr. Eduardo Liceaga,” Mexico City, MexicoDepartment of Gastroenterology and Hepatology, General Hospital of México “Dr. Eduardo Liceaga,” Mexico City, MexicoResearch Department General Hospital of Mexico “Dr. Eduardo Liceaga,” Mexico City, MexicoResearch Department General Hospital of Mexico “Dr. Eduardo Liceaga,” Mexico City, MexicoDepartment of Gastroenterology and Hepatology, General Hospital of México “Dr. Eduardo Liceaga,” Mexico City, MexicoDepartment of Gastroenterology and Hepatology, General Hospital of México “Dr. Eduardo Liceaga,” Mexico City, MexicoResearch Department General Hospital of Mexico “Dr. Eduardo Liceaga,” Mexico City, Mexico; Sleep Disorders Clinic, Department of Experimental Medicine, Faculty of Medicine, UNAMIntroduction and Objectives: The clinical alterations of Minimal Hepatic Encephalopathy (MHE) include subtle changes in cognitive processes detectable only with tests such as the Psychometric hepatic encephalopathy score (PHES) and critical blink rate (FCP) or P300 cognitive evoked potentials. After treatment with L-Ornithine, L-Aspartate (LOLA) 18 grams/30 days, a decrease or normalization in the PHES score, an increase in FCP, and a reduction in the latency of the P300 potential have been observed. In the short term, it is unknown if there are changes in these three indicators of the cognitive status of patients with MHE. This study aimed to detect changes in the potential cognitive P300 of patients treated with LOLA 18g/3 days. Materials and Methods: Cirrhotic patients who attended the Liver Clinic of the Gastroenterology Service of the General Hospital of Mexico ''Eduardo Liceaga'' were included. The PHES test and FCP were applied, and the electroencephalogram (EEG) was recorded while visual stimuli were presented in a cognitive task to obtain the potential P300. The criteria for MHE were a PHES test score of less than -4 standard deviations (sd) and an FCP score of less than 39.0 Hz. EHM patients were given LOLA 6g/3 times a day for three days. Subsequently, the PHES, FCP, and P300 tests were repeated. Results: 89 patients with liver cirrhosis participated, 54 women (60.7%) with 53±7.9 years of age and 8.3±3.4 years of schooling. Fifty-seven patients (64.0%) were positive for PHES and 64 were positive for FCP (71.9%). EHM (positive for PHES and FCP) was detected in 53 patients (59.6%). Thirty-six patients (68%) accepted treatment with LOLA or completed the three tests, of which 16 repeated the three tests. The median PHES before treatment was -5.0 ds(-1,-6) and after treatment with LOLA -3.0 ds(-2,-4). The difference was significant in the Wilcoxon test for paired samples p<0.0001. The initial mean of the FCP was 37.03±1.8 Hz and the final was 39.8±2.1 Hz. The difference was significant for the student's t-test for related samples p<0.0001. The P300 potential had an initial amplitude of 2.42±2.79 and a final one of 2.21±2.19, not being significant, in contrast to the initial latency of 410.06±63 milliseconds (ms) and the final one of 404.88±63.6 ms, being significant after treatment. with LOLA p=0.015 Conclusions: Short-term (3 days) changes in MHE due to LOLA treatment were seen in PHES test scores, FCP test scores, and P300 evoked potentials. The P300 potentials reflect the state of the EEG when performing cognitive tasks of attention. The improvement in this indicator is already known at 30 days of treatment and with the present study, it was determined that immediately at the start of treatment with LOLA, there is an improvement in their cognitive status.http://www.sciencedirect.com/science/article/pii/S1665268123000595 |
| spellingShingle | José Luis Pérez-Hernández Christian Hinojosa-Segura Diana Montemira-Orozco Andrés Burak-Leipuner Juana Zavala-Ramírez Imram Cruz-Reyes María Escobedo-Silva Fátima Higuera-de la Tijera Daniel Santana-Vargas P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE Annals of Hepatology |
| title | P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE |
| title_full | P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE |
| title_fullStr | P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE |
| title_full_unstemmed | P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE |
| title_short | P 56- SHORT-TERM RESPONSE OF P300 EVOKED POTENTIAL IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY TREATED WITH L-ORNITHINE, L-ASPARTATE |
| title_sort | p 56 short term response of p300 evoked potential in patients with minimal hepatic encephalopathy treated with l ornithine l aspartate |
| url | http://www.sciencedirect.com/science/article/pii/S1665268123000595 |
| work_keys_str_mv | AT joseluisperezhernandez p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT christianhinojosasegura p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT dianamontemiraorozco p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT andresburakleipuner p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT juanazavalaramirez p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT imramcruzreyes p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT mariaescobedosilva p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT fatimahigueradelatijera p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate AT danielsantanavargas p56shorttermresponseofp300evokedpotentialinpatientswithminimalhepaticencephalopathytreatedwithlornithinelaspartate |